[Testosterone and mortality]

Area of Science:

• Endocrinology
• Gerontology
• Cardiovascular Medicine

Background:

• Subnormal testosterone levels (hypogonadism) are common in aging men and associated with comorbidities like cardiovascular disease, obesity, and diabetes.
• The causal relationship between testosterone deficiency and these conditions (atherosclerosis, metabolic syndrome) is not fully understood.
• Hypogonadism is a potential risk factor for significant morbidity and mortality.

Purpose of the Study:

• To investigate the impact of testosterone deficiency and supplementation on health outcomes in aging men.
• To clarify the role of testosterone in the development of cardiovascular disease and metabolic syndrome.
• To assess the benefits and risks of testosterone supplementation on symptoms, well-being, and mortality.

Main Methods:

• Observational studies correlating testosterone levels with health status and mortality.
• Clinical trials evaluating the effects of testosterone supplementation in hypogonadal men.
• Analysis of changes in sexual function, mood, vitality, and cardiovascular risk factors.

Main Results:

• Hypogonadal men exhibit lower life expectancy and are prone to cardiovascular disease, obesity, and diabetes.
• Testosterone supplementation improved sexual activity, well-being, and depressive symptoms moderately.
• A beneficial effect on cardiovascular risk factors was observed, but a reduction in mortality was not definitively established.

Conclusions:

• Testosterone deficiency is linked to increased morbidity and potentially reduced life expectancy in aging men.
• Testosterone supplementation offers benefits for specific symptoms and cardiovascular risk factors.
• Further research is needed to determine if testosterone therapy impacts overall mortality.